Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder

Clin EEG Neurosci. 2017 Jul;48(4):246-250. doi: 10.1177/1550059416675232. Epub 2016 Oct 25.

Abstract

EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.

Keywords: EEG biomarker; attention-deficit/hyperactivity disorder; methylphenidate; relative power; theta/beta ratio.

MeSH terms

  • Adolescent
  • Antidepressive Agents / administration & dosage
  • Attention Deficit Disorder with Hyperactivity / diagnosis*
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / physiopathology
  • Biomarkers
  • Brain Waves / drug effects*
  • Central Nervous System Stimulants / administration & dosage*
  • Child
  • Dextroamphetamine / administration & dosage
  • Dopamine Antagonists / administration & dosage
  • Drug Monitoring
  • Electroencephalography / drug effects*
  • Electroencephalography / methods*
  • Female
  • Humans
  • Male
  • Methylphenidate / administration & dosage
  • Observer Variation
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Biomarkers
  • Central Nervous System Stimulants
  • Dopamine Antagonists
  • Methylphenidate
  • Dextroamphetamine